Cape Fear BioCapital
- Company typePrivate
- Founded-
- HeadquartersDurham, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Cape Fear BioCapital firmographics
Firmographics- Name
- Cape Fear BioCapital
- Legal name
- Cape Fear BioCapital
- Website
- https://capefearbiocap.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Cape Fear BioCapital industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Venture Capital (CVC) (FSANAAAF)
- akta.pro secondary industry
- Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)
Keywords
Where Cape Fear BioCapital is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cape Fear BioCapital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Revenue model
- Venture Capital Returns (Carried Interest): Returns on investment through equity ownership in portfolio companies (Thoracic Innovations, Ten63 Therapeutics, Incyclix Bio, iOrganBio, EnFuego Therapeutics, Eldec Pharmaceuticals). Returns realized through portfolio company exits, M&A, or IPO events.
- Management Fees: Management fees charged to fund limited partners (LPs) for managing the venture capital fund, covering operational costs of fund administration and portfolio monitoring.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Cape Fear BioCapital product offering
Product offeringCore offering
Cape Fear BioCapital is an early-stage venture capital firm that writes first checks and joins syndicates in pre-seed to seed-stage therapeutics companies emerging from North Carolina's academic research ecosystem (Duke, UNC, NC State). The firm targets companies within three years of an IND filing, providing capital, hands-on company-building support, and a network of clinical and regulatory resources to advance promising academic science into clinical development.
Product overview
Cape Fear BioCapital is an early-stage venture capital firm focused on investing in therapeutics companies in North Carolina. The firm does not offer a unified product platform but provides investment capital and operational support to its portfolio companies. Cape Fear BioCapital backs companies across various stages (Pre-Seed to Series B) and therapeutic modalities including AI drug discovery, small molecules, MedTech, biologics/RNAi, and peptide therapeutics. Their portfolio companies include: Thoracic Innovations (MedTech for cardiothoracic surgery), Ten63 Therapeutics (AI-enabled drug discovery using the BEYOND platform), Incyclix Bio (CDK2 inhibitor for oncology), iOrganBio (AI-powered cell manufacturing via CellForge platform), EnFuego Therapeutics (siRNA platform for oncology), and Eldec Pharmaceuticals (peptide therapeutics for respiratory disease).
Differentiator
Problem solved
Functional benefit
Products and services
- Early-Stage Therapeutics Venture Capital Investment
Companies that use Cape Fear BioCapital
Customer profileSegments1 record
Ideal customer profiles1 record
Cape Fear BioCapital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cape Fear BioCapital partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ParexelcoreParexel, a global clinical development partner, announced an inaugural partnership with Cape Fear BioCapital at the launch of the Parexel Biotech Incubator at its North Hills Innovation District headquarters in Raleigh, North Carolina. The partnership is designed to connect early-stage therapeutics companies with clinical and regulatory expertise, addressing the gap where seed-stage investment and clinical development expertise rarely come together at the right time. Parexel has continued to invest in North Carolina since establishing its Durham location in 2014 and opened its global headquarters in Raleigh in 2025. This is a flagship partnership for Cape Fear BioCapital's portfolio companies, providing them with access to Parexel's global clinical and regulatory capabilities.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Cape Fear BioCapital competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key highlights5 records
Customer concentration
Cape Fear BioCapital social profiles
Digital presenceCape Fear BioCapital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cape Fear BioCapital leadership team
Management profileNumber of profiles
Profiles3 records
Cape Fear BioCapital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cape Fear BioCapital M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cape Fear BioCapital
What does Cape Fear BioCapital do?
Cape Fear BioCapital is an early-stage venture capital firm that writes first checks and joins syndicates in pre-seed to seed-stage therapeutics companies emerging from North Carolina's academic research ecosystem (Duke, UNC, NC State). The firm targets companies within three years of an IND filing, providing capital, hands-on company-building support, and a network of clinical and regulatory resources to advance promising academic science into clinical development.
Is Cape Fear BioCapital a public or private company?
Cape Fear BioCapital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cape Fear BioCapital founded?
Cape Fear BioCapital was founded in -1. It employs 1 to 10 people.
Where is Cape Fear BioCapital based?
Cape Fear BioCapital is headquartered in Durham, United States, in the North America region.
How does Cape Fear BioCapital make money?
Two revenue lines are on record. Venture Capital Returns (Carried Interest) is the primary driver. The others are management Fees.
Does Cape Fear BioCapital have an API?
No public API is recorded for Cape Fear BioCapital.
What industry is Cape Fear BioCapital in?
Cape Fear BioCapital's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAF, Corporate Venture Capital (CVC), with a secondary code of FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms. Its NAICS code is 523940 and its SIC code is 6282.